Additional Hetero Ring Attached Directly Or Indirectly To The Four-membered Hetero Ring By Nonionic Bonding Patents (Class 514/210.18)
-
Patent number: 9598424Abstract: The present invention provides compounds of formula 1: which are useful as inhibitors of TBK-1, pharmaceutical compositionst thereof, methods for treatment of conditions associated with TBK1, processes for making the compounds and intermediates thereof.Type: GrantFiled: February 12, 2015Date of Patent: March 21, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Walter Keung, Lily Kwok, Mark Sabat, Nicholas Scorah, Haixia Wang, Steven John Woodhead, Anthony R Gangloff
-
Patent number: 9598422Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.Type: GrantFiled: November 5, 2015Date of Patent: March 21, 2017Assignee: Flexus Biosciences, Inc.Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Steven P. Seitz, Emily Charlotte Cherney, Liping Zhang, Weifang Shan, Weiwei Guo, Audris Huang
-
Patent number: 9567334Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.Type: GrantFiled: March 22, 2016Date of Patent: February 14, 2017Assignee: Principia Biopharma, Inc.Inventors: Erik Verner, Kenneth Albert Brameld
-
Patent number: 9562036Abstract: The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.Type: GrantFiled: June 17, 2016Date of Patent: February 7, 2017Assignee: GRÜNENTHAL GMBHInventors: Melanie Reich, Stefan Schunk, Florian Jakob, Henning Steinhagen, Nils Damann, Michael Haurand, Marc Rogers, Kathy MacKenzie
-
Patent number: 9561228Abstract: Compounds, compositions thereof, and methods for inhibiting one or both ERK1 and ERK2 kinases are provided.Type: GrantFiled: February 7, 2014Date of Patent: February 7, 2017Assignee: Celgene Avilomics Research, Inc.Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu
-
Patent number: 9556197Abstract: The present disclosure describes furo- and thieno-pyridine carboxamide compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.Type: GrantFiled: August 22, 2014Date of Patent: January 31, 2017Assignee: Incyte CorporationInventors: Yun-Long Li, David M. Burns, Hao Feng, Taisheng Huang, Song Mei, Jun Pan, Oleg Vechorkin, Hai-Fen Ye, Wenyu Zhu, Maria Rafalski, Anlai Wang, Chu-Biao Xue
-
Patent number: 9550755Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: June 27, 2013Date of Patent: January 24, 2017Assignee: NOVARTIS AGInventors: Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
-
Patent number: 9546153Abstract: Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a bicyclic heterocycle, and R1, R3, R4, R5 and R6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.Type: GrantFiled: November 7, 2013Date of Patent: January 17, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Rajeev S. Bhide, John V. Duncia, John Hynes, Satheesh K. Nair, William J. Pitts, Sreekantha R. Kumar, Daniel S. Gardner, Natesan Murugesan, Venkatram Reddy Paidi, Joseph B. Santella, Ramesh Sistla, Hong Wu
-
Patent number: 9540349Abstract: The invention relates to novel substituted pyrimidine compounds of general formula (I) in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.Type: GrantFiled: July 15, 2015Date of Patent: January 10, 2017Assignee: GRUENENTHAL GMBHInventors: Antonio Nardi, Florian Jakob, Ingo Konetzki, Tobias Craan, Christian Hesslinger
-
Patent number: 9518067Abstract: The invention provides compositions and methods for mass spectrometric (MS), organic synthesis, and applications of organo-trifluoroborate, for example, as mass tags for use in negative ion mode. When subject to MS fragmentation, organo-trifluoroborates preferentially undergo neutral losses of hydrogen fluoride (HF) or boron trifluoride (BF3) molecules, transferring the negative charge to the rest of the molecule. Such a fragmentation pattern is used to detect and quantitate analytes of interest after derivatization with organo-trifluoroborates.Type: GrantFiled: April 23, 2016Date of Patent: December 13, 2016Assignee: CellMosaic, Inc.Inventor: Yumei Huang
-
Patent number: 9493464Abstract: The invention provides compounds that inhibit the degradation of Wee1. The compounds of the present invention are generally N-((1H-benzo[d]imidazol-2-yl)methyl)-9H-purin-6-amines. Compounds of the invention can be used for treatment of malconditions in patients for which inhibition of Wee1 is medically indicated, for example cancer, Alzheimer's, neurological disorders, psychiatric disorders, or inflammation-related disorders.Type: GrantFiled: February 26, 2013Date of Patent: November 15, 2016Assignee: The Scripps Research InstituteInventors: William R. Roush, Ronald Rahaim, Mathieu Bibian
-
Patent number: 9487483Abstract: The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: June 27, 2013Date of Patent: November 8, 2016Assignee: Novartis AGInventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Jean Quancard, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti, Stefanie Flohr
-
Patent number: 9487504Abstract: The present invention provides novel imidazole analogs of Formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.Type: GrantFiled: June 18, 2013Date of Patent: November 8, 2016Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.Inventors: Jongwon Lim, Michael H. Reutershan, John Michael Ellis, Kaleen Konrad Childers, Anthony Donofrio, Michael D. Altman, Andrew M. Haidle, Anna Zabierek, Matthew Christopher, Jonathan Grimm, Jason Burch, Maria Emilia Di Francesco, Alessia Petrocchi, Christian Beaulieu, Vouy Linh Truong, Alan B. Northrup, Marc Blouin
-
Patent number: 9464089Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.Type: GrantFiled: July 11, 2014Date of Patent: October 11, 2016Assignee: ACEA BIOSCIENCES INC.Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
-
Patent number: 9458132Abstract: Compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.Type: GrantFiled: November 8, 2013Date of Patent: October 4, 2016Assignee: AGIOS PHARMACEUTICALS, INCInventors: Giovanni Cianchetta, Janeta Popovici-Muller, Jeffrey O. Saunders, Robert Zahler
-
Patent number: 9453015Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.Type: GrantFiled: February 25, 2015Date of Patent: September 27, 2016Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Akihiro Okano, Fumihiko Saitoh
-
Patent number: 9434723Abstract: Heteroarylpiperidine and -piperazine derivatives of the formula (I) in which the symbols A, X, Y, L1, L2, G, Q, p, R1, R2 and R10 are each as defined in the description, and salts, metal complexes and N-oxides of the compounds of the formula (I), and the use thereof for controlling phytopathogenic harmful fungi and processes for preparing compounds of the formula (I).Type: GrantFiled: March 4, 2015Date of Patent: September 6, 2016Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Tomoki Tsuchiya, Pierre Wasnaire, Sebastian Hoffmann, Pierre Cristau, Thomas Seitz, Joachim Kluth, Stefan Hillebrand, Juergen Benting, Daniela Portz, Ulrike Wachendorff-Neumann
-
Patent number: 9434714Abstract: The invention provides novel imidazole amine compounds according to formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.Type: GrantFiled: February 10, 2015Date of Patent: September 6, 2016Assignee: Merck Patent GmbHInventors: Ruoxi Lan, Xiaoling Chen, Yufang Xiao, Bayard R. Huck, Andreas Goutopoulos
-
Patent number: 9428478Abstract: The disclosure relates to piperazine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidase.Type: GrantFiled: June 12, 2012Date of Patent: August 30, 2016Assignee: Emory UniversityInventors: Thota Ganesh, Aiming Sun, Susane M. Smith, John David Lambeth
-
Patent number: 9428502Abstract: Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.Type: GrantFiled: December 31, 2014Date of Patent: August 30, 2016Assignee: 3-V Biosciences, Inc.Inventors: Johan D. Oslob, Robert S. McDowell, Russell Johnson, Hanbiao Yang, Marc Evanchik, Cristiana A. Zaharia, Haiying Cai, Lily W. Hu, Allan S. Wagman
-
Patent number: 9428509Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.Type: GrantFiled: January 15, 2014Date of Patent: August 30, 2016Assignee: Signal Pharmaceuticals, LLCInventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning, Shuichan Xu
-
Patent number: 9416125Abstract: Compounds of formula (I), processes for their production and their use as Bub1 kinase inhibitors for the treatment of hyperproliferative diseases and/or disorders responsive to induction of cell death.Type: GrantFiled: May 8, 2013Date of Patent: August 16, 2016Assignee: Bayer Pharma AktiengesellschaftInventors: Marion Hitchcock, Christoph-Stephan Hilger, Anne Mengel, Hans Briem, Simon Holton, Vera Pütter, Gerhard Siemeister, Stefan Prechtl, Amaury Ernesto Fernández-Montalván, Christian Stegmann, Cornelia Preuβe, Mark Jean Gnoth
-
Patent number: 9415049Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: GrantFiled: December 20, 2013Date of Patent: August 16, 2016Assignee: Celgene Avilomics Research, Inc.Inventors: Richland Tester, Prasoon Chaturvedi, Zhendong Zhu, Sekhar S. Surapaneni, Lisa Beebe
-
Patent number: 9382257Abstract: Compounds having the formula I wherein R1 and R2 are as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.Type: GrantFiled: April 16, 2015Date of Patent: July 5, 2016Assignee: Genentech, Inc.Inventors: Daniel Burdick, Huifen Chen, Shumei Wang, Weiru Wang
-
Patent number: 9376448Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: GrantFiled: October 17, 2013Date of Patent: June 28, 2016Assignee: Vertex Pharmaceuticals IncorporatedInventors: Paul S. Charifson, Kevin Michael Cottrell, Hongbo Deng, John P. Duffy, Huai Gao, Simon Giroux, Jeremy Green, Katrina Lee Jackson, Joseph M. Kennedy, David J. Lauffer, Mark Willem Ledeboer, Pan Li, John Patrick Maxwell, Mark A. Morris, Albert Charles Pierce, Nathan D. Waal, Jinwang Xu
-
Patent number: 9365519Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.Type: GrantFiled: February 11, 2015Date of Patent: June 14, 2016Assignee: Epizyme, Inc.Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin
-
Patent number: 9346815Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.Type: GrantFiled: May 22, 2015Date of Patent: May 24, 2016Assignee: Genentech, Inc.Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-Wai Yuen
-
Patent number: 9309238Abstract: Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to imidazopyridine compounds, synthesis thereof, and methods of using same. Disclosed herein are various imidazo[1,2-a]pyhdine compounds and methods of using the novel compounds to treat or prevent tuberculosis in a subject or to inhibit fungal growth on plant species. Other embodiments include methods of synthesizing imidazo[1,2-a]pyridine compounds, such as the disclosed imidazo[1,2-a]pyridine compounds.Type: GrantFiled: November 5, 2010Date of Patent: April 12, 2016Assignee: UNIVERSITY OF NOTRE DAME DU LACInventors: Marvin J. Miller, Garrett C. Moraski, Lowell D. Markley, George E. Davis
-
Patent number: 9290457Abstract: Substituted dihydropyrimidinones of formula 1 which are inhibitors of neutrophil elastase activity and which are useful as medicaments for the treatment of, inter alia, COPD.Type: GrantFiled: July 27, 2015Date of Patent: March 22, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Stefan Peters, Ralf Anderskewitz, Gerd Morschhaeuser, Thorsten Oost
-
Patent number: 9273028Abstract: The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.Type: GrantFiled: October 28, 2011Date of Patent: March 1, 2016Assignees: Biogen MA Inc., Sunesis Pharmaceuticals, Inc.Inventors: Brian T. Hopkins, Daniel Scott, Patrick Conlon, Tracy J. Jenkins, Noel Powell, Bing Guan, Julio H. Cuervo, Deping Wang, Art Taveras
-
Patent number: 9266904Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as or pharmaceutically acceptable salts, or tautomerism isomers, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds.Type: GrantFiled: May 16, 2014Date of Patent: February 23, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Lei Guo, Taishan Hu, Yimin Hu, Buelent Kocer, Buyu Kou, Gangqin Li, Xianfeng Lin, Haixia Liu, Hong Shen, Houguang Shi, Guolong Wu, Zhisen Zhang, Mingwei Zhou, Wei Zhu
-
Patent number: 9266867Abstract: The present invention relates to novel compounds acting as agonists at S1P (sphingosine-1-phosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation.Type: GrantFiled: April 10, 2012Date of Patent: February 23, 2016Assignees: BIOPROJET, SUN PHARMA ADVANCED RESEARCH COMPANY LTDInventors: Marc Capet, Isabelle Berrebi-Bertrand, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte, Rajamannar Thennati, Ranjan Kumar Pal, Biswajit Samanta, Muthukumaran Natarajan Pillai, Japan Nitinkumar Desai, Dijixa Chandubhai Rana, Kaushik Dhanjubhai Prajapati, Sandeep Pankajbhai Pathak, Bhavesh M. Panchal, Jayraj D. Aradhye
-
Patent number: 9255110Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.Type: GrantFiled: April 2, 2014Date of Patent: February 9, 2016Assignees: ROCHE PALO ALTO LLC, HOFFMANN-LA ROCHE INC.Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
-
Patent number: 9233983Abstract: The present disclosure provides hetero-bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.Type: GrantFiled: October 8, 2014Date of Patent: January 12, 2016Assignee: ADVINUS THERAPEUTICS LIMITEDInventors: Mahesh Thakkar, Summon Koul, Debnath Bhuniya, Kasim Mookhtiar, Santosh Kurhade, Yogesh Munot, Tanaji Mengawade, Bheemashankar A. Kulkarni
-
Patent number: 9226928Abstract: The present invention relates to a novel antiparasitic composition comprising an effective amount of a) a Formula (1) compound, wherein R1a, R1b, R1c, R2, R3, R4, and n are as defined herein, stereoisomer thereof, or a pharmaceutical or veterinary acceptable salt thereof, b) a macrocyclic lactone or derivative thereof and c) optionally, at least one additional veterinary agent, and further comprising at least one veterinary or pharmaceutical acceptable carrier; and a method of treating an animal with a parasitic infection, by administering an effective amount of said composition to the animal in need thereof.Type: GrantFiled: September 4, 2013Date of Patent: January 5, 2016Assignee: Zoetis Services LLCInventors: Nathan Anthony Logan Chubb, Kevin Evans, Tom L. McTier, Patrick F. M. Meeus
-
Patent number: 9221834Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substituted phenyl group or indanyl group. Formula (I).Type: GrantFiled: October 25, 2011Date of Patent: December 29, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Zhijian Lu, Yi-Heng Chen, Cameron Smith, Hong Li, Christopher F. Thompson, Julianne Hunt, Florida Kallashi, Ramzi Sweis, Peter Sinclair, Samantha E. Adamson, Guizhen Dong, Debra L. Ondeyka, Xiaoxia Qian, Wanying Sun, Petr Vachal, Kake Zhao
-
Patent number: 9199981Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFR?, PDGFR?) kinases.Type: GrantFiled: August 27, 2012Date of Patent: December 1, 2015Assignee: NOVARTIS AGInventors: Vince Yeh, Xiaolin Li, Xiaodong Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Bao Nguyen, Hank Michael James Petrassi
-
Patent number: 9181271Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.Type: GrantFiled: October 31, 2013Date of Patent: November 10, 2015Assignees: Incyte Holdings Corporation, Incyte CorporationInventors: Yun-Long Li, Wenyu Zhu, Song Mei
-
Patent number: 9181246Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.Type: GrantFiled: July 28, 2014Date of Patent: November 10, 2015Assignee: AbbVie Inc.Inventors: Thomas D. Penning, Keith W. Woods, Chunqiu Lai, Alan S. Florjancic, Yunsong Tong
-
Patent number: 9163017Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: GrantFiled: September 9, 2013Date of Patent: October 20, 2015Assignee: ABBVIE INC.Inventors: David A. Degoey, Pamela L. Donner, Warren M. Kati, Charles W. Hutchins, Mark A. Matulenko, Tammie K. Jinkerson, Ryan G. Keddy
-
Patent number: 9156811Abstract: The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.Type: GrantFiled: August 29, 2009Date of Patent: October 13, 2015Assignee: Univeristy of DundeeInventors: Stephen Brand, Paul Wyatt, Stephen Thompson, Victoria Smith, Tracy Bayliss, Justin Harrison, Neil Norcross, Laura Cleghorn, Ian Gilbert, Ruth Brenk
-
Patent number: 9150522Abstract: Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.Type: GrantFiled: October 25, 2012Date of Patent: October 6, 2015Assignees: Peking University Shenzhen Graduate School, Beijing Reciprocapharmaceuticals Co. Ltd.Inventors: Zhengying Pan, Xitao Li
-
Patent number: 9120784Abstract: The present invention relates to substituted 1,3,4-oxadiazoles-2-thio azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: November 4, 2013Date of Patent: September 1, 2015Assignee: Allergan, Inc.Inventors: Janet A. Takeuchi, Ling Li, Wha-Bin Im, Ken Chow
-
Patent number: 9108993Abstract: The present invention relates to pyrazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: February 24, 2014Date of Patent: August 18, 2015Assignee: Allergan, Inc.Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im, Ken Chow
-
Patent number: 9096579Abstract: The invention relates to new amino-indole-substituted imidazolyl-pyrimidines of formula 1 wherein R1, R2, R3, R4 and R5 are defined as in claim 1 and pharmaceutically acceptable salts thereof and the use of these compounds for the preparation of a medicament for treating a disease selected from asthma, COPD, rheumatoid arthritis, specific lymphomas and specific diseases of the nervous system.Type: GrantFiled: April 17, 2013Date of Patent: August 4, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Georg Dahmann, Horst Dollinger, Christian Gnamm, Dennis Fiegen, Matthias Hoffmann, Jasna Klicic, David James Lamb, Andreas Schnapp
-
Patent number: 9090562Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.Type: GrantFiled: May 12, 2014Date of Patent: July 28, 2015Assignee: Epizyme, Inc.Inventors: Kevin Wayne Kuntz, Richard Chesworth, Kenneth William Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah Kathleen Knutson, Timothy James Nelson Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
-
Patent number: 9073912Abstract: This invention recites substituted azetidine derivatives of Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, and their use as a parasiticide in animals. The substituents A, B, R1a, R1b, R1c, R2, R3, R4, R6, and n are as described herein.Type: GrantFiled: May 6, 2013Date of Patent: July 7, 2015Assignee: Zoetis Services LLCInventors: Susan M. K. Sheehan, Valerie A. Vaillancourt
-
Patent number: 9062041Abstract: The present invention relates to novel 2H-indazoles of the general formula (I), methods for the preparation thereof and the use thereof for the production of pharmaceutical agents for the treatment of diseases and indications which are linked with the EP2-receptor.Type: GrantFiled: November 26, 2012Date of Patent: June 23, 2015Assignee: Bayer Intellectual Property GmbHInventors: Nico Bräuer, Anne Mengel, Ulrike Charlotte Röhn, Andrea Rotgeri, Bernd Buchmann, Bernhard Lindenthal, Antonius Ter Laak
-
Patent number: 9056865Abstract: The present application relates to compounds of Formula (I), and Formula (II), or pharmaceutically acceptable salt thereof, wherein A, X, Y, Z, e, f, R1, R2, R3, R4, R5, R5b, R6, R7, R8, R9, R10, R11, R20, R21, R22 and R23 are defined herein. These novel pyridine derivatives that are useful in therapy, in particular for treating diseases or conditions mediated by Smo, including the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to methods of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.Type: GrantFiled: October 19, 2011Date of Patent: June 16, 2015Assignee: Pfizer Inc.Inventors: Sajiv Krishnan Nair, Simon Paul Planken
-
Publication number: 20150148327Abstract: The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.Type: ApplicationFiled: June 17, 2013Publication date: May 28, 2015Applicant: Merck Canada Inc.Inventors: Andrew M. Haidle, Sandra Lee Knowles, Solomon D. Kattar, Denis Deschenes, Jason Burch, Joel Robichaud, Matthew Christopher, Michael D. Altman, James P. Jewell, Alan B. Northrup, Marc Blouin, John Michael Ellis, Hua Zhou, Christian Fischer, Adam J. Schell, Michael H. Reutershan, Brandon M. Taoka, Anthony Donofrio, Joel Robichaud